ROCKAWAY, N.J. , July 06, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that its gammaCore non-invasive vagus nerve stimulation (“nVNS”) has been selected to be a part of studies on effects of cannabinoids
ROCKAWAY, N.J. , June 27, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that its TAC-STIM non-invasive vagus nerve stimulation (“nVNS”) Human Performance product, has been selected to be a part of the Air
ROCKAWAY, N.J. , June 14, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that Company CEO, Dan Goldberger , will present at the Healthcare Virtual Conference Part II, presented by Maxim Group LLC and hosted
ROCKAWAY, N.J. , June 13, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that “SUNCT/ SUNA with neurovascular conflict: consider nVNS,” will be presented at the American Headache Society’s 65 th Annual
ROCKAWAY, N.J. , May 26, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the resignation of its Founder and former CEO, JP Errico from the Board of Directors. Mr.
ROCKAWAY, N.J. , May 23, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR) a commercial-stage bioelectronic medicine and wellness company, today announced that electroCore’s Chief Executive Officer, Dan Goldberger , will present at the 13th Annual LD Micro Invitational XIII
Record first quarter 2023 net sales of $2.8 million , approximately 46% over first quarter 2022 Company to host a conference call and webcast today, May 3, 2023 , at 4:30 PM EDT ROCKAWAY, N.J. , May 03, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic
ROCKAWAY, N.J. , May 01, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR) a commercial-stage bioelectronic medicine and wellness company, today announced that electroCore’s Chief Executive Officer, Dan Goldberger , will present at the Annual Aegis Virtual Conference being
ROCKAWAY, N.J. , April 26, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health (NIH), has awarded Emory University and
Clinical trial (n=36) shows the ability of gammaCore (nVNS) to significantly improve the recall of a foreign language compared to sham while simultaneously showing improved focus and decreased fatigue in study participants ROCKAWAY, N.J. , April 24, 2023 (GLOBE NEWSWIRE) -- electroCore,